Did you mean aromatase inhibitor?
Displaying drugs 401 - 425 of 2438 in total
Caplacizumab
Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy...
Approved
Investigational
Matched Categories: … von Willebrand Factor, antagonists & inhibitors …
Moxetumomab pasudotox
CD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma. The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22. This antibody was used to...
Approved
Investigational
Matched Categories: … CD22 (Clusters of Differentiation 22) inhibitors …
Amsacrine
Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors …
Rescinnamine
Rescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from Rauwolfia serpentina and other species of Rauwolfia.
Approved
Matched Categories: … Angiotensin-Converting Enzyme Inhibitors …
Sonidegib
Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Approved
Investigational
Matched Categories: … Hedgehog pathway inhibitors …
Metergoline
Metergoline is an ergot-derived psychoactive drug that acts as a ligand for serotonin and dopamine receptors. Metergoline is an antagonist at various 5-HT receptor subtypes at a relatively low concentration and agonist at dopamine receptors. Its use has been studied in various clinical settings such as a treatment for seasonal...
Approved
Matched Categories: … Prolactine Inhibitors …
Cetirizine
Cetirizine, also commonly known as Zyrtec, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , .
One of the most common uses for this drug is for a condition called allergic...
Approved
Matched Categories: … P-glycoprotein inhibitors …
Golimumab
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with...
Approved
Matched Categories: … Tumor necrosis factor alpha (TNF-alpha) inhibitors …
Enfortumab vedotin
Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to brentuximab vedotin, another...
Approved
Investigational
Matched Categories: … Microtubule Inhibitors …
Desloratadine
Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors …
Trastuzumab emtansine
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis....
Approved
Investigational
Matched Categories: … Microtubule Inhibitors ... HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors …
Salicylamide
Salicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties. It has similar medicinal uses to aspirin. Salicylamide is used in combination with both aspirin and caffeine in the over-the-counter pain remedies
Approved
Matched Categories: … Cyclooxygenase Inhibitors …
Valbenazine
Valbenazine is a modified metabolite of tetrabenazine, and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of tetrabenazine,...
Approved
Investigational
Matched Categories: … Vesicular Monoamine Transporter 2 Inhibitors …
Ponesimod
Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults.[A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than fingolimod. Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to...
Approved
Investigational
Matched Categories: … Receptors, Lysosphingolipid, antagonists & inhibitors …
Leucovorin
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro, the...
Approved
Matched Categories: … OAT3/SLC22A8 Inhibitors …
Azathioprine
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of...
Approved
Matched Categories: … Nucleic Acid Synthesis Inhibitors …
Aminophylline
Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Similar to other theophyllines, aminophylline is indicated for the treatment of lung diseases such as asthma,...
Approved
Matched Categories: … Enzyme Inhibitors ... Phosphodiesterase Inhibitors …
Prenylamine
Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.
Approved
Withdrawn
Matched Categories: … Calmodulin, antagonists & inhibitors …
Piperacillin
Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.
Approved
Matched Categories: … OAT1/SLC22A6 inhibitors …
Inclisiran
Inclisiran is a long-acting, synthetic small interfering RNA (siRNA) directed against proprotein convertase subtilisin-kexin type 9 (PCSK9), which is a serine protease that regulates plasma low-density lipoprotein cholesterol (LDL-C) levels. By binding to PCSK9 messenger RNA, inclisiran prevents protein translation of PCSK9, leading to decreased concentrations of PCSK9 and plasma...
Approved
Investigational
Matched Categories: … Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors …
Pegvisomant
Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
Approved
Matched Categories: … Cholinesterase Inhibitors …
Bendroflumethiazide
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)
Approved
Matched Categories: … Sodium Chloride Symporter Inhibitors …
Sulpiride
Sulpiride first appeared in published literature in 1967. Clinical studies show a greater effect on treating the negative symptoms of schizophrenia rather than positive symptoms at low doses, though the effects are more equal at higher doses. Sulpiride is not approved by the FDA, Health Canada, or the EMA; though...
Approved
Investigational
Matched Categories: … Cholinesterase Inhibitors …
Levodopa
Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent...
Approved
Matched Categories: … Levodopa, antagonists & inhibitors …
Clobetasol propionate
Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors. It has demonstrated superior activity compared to fluocinonide and was first described in the literature in 1974. Clobetasol Propionate was granted FDA approval on 27 December 1985.
Approved
Matched Categories: … Thyroxine-binding globulin inhibitors …
Displaying drugs 401 - 425 of 2438 in total